Cardiff Oncology CRDF
NASDAQ CRDF
$0.94 +0.01 (+0.81%)
At close: Oct 21, 2026 · 4:00 PM EDT

Cardiff Oncology (CRDF) Cash from Restructuring (2017 - 2018)

Updated

Analysis

Cardiff Oncology (CRDF) Cash from Restructuring (2017 - 2018) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 Cardiff Oncology 65.24 Mn 30.74 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2018 187,500.00
Dec 31, 2017 104,700.00
Mar 31, 2017 485,000.00
API Access

Cardiff Oncology Cash from Restructuring API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-from-restructuring&ticker=CRDF&period=max&api_key=YOUR_API_KEY